Downloads: 1
| # | Blank 1 | Frequency | Blank 2 | Frequency | |
|---|---|---|---|---|---|
| 1 | 1 | tumor in a location where enlargement comcLd cause | 7 | obstruction | 17 |
| 2 | 2 | exclusion treatment tumor in a location where enlargement comcLd cause | 1 | 1 | |
| 3 | 3 | treatment exclusion tumor in a location where enlargement comcLd cause | 1 | NA | |
| 4 | 4 | cell procurement subjects must not have tumor in a location where enlargement comcLd cause | 1 | NA | |
| 5 | 5 | lymphodepletion subjects must not have tumor in a location where enlargement comcLd cause | 1 | NA | |
| 6 | 6 | prior to cell procurement tumor in a location where enlargement comcLd cause | 1 | NA | |
| 7 | 7 | prior to lymphodepletion tumor in a location where enlargement comcLd cause | 1 | NA | |
| 8 | 8 | prior to infusion of atlcar . cd30 cells tumor in a location where enlargement comcLd cause | 1 | NA | |
| 9 | 9 | patients must not have tumor in a location where enlargement comcLd cause | 1 | NA | |
| 10 | 12 | no evidence of tumor potentially causing | 1 | NA | |
| 11 | 16 | fixed upper | 1 | NA | |
| 12 | 17 | measurable disease with obstruction into the | 1 | NA |